Growth Equity
Ampersand Capital
Ampersand Capital takes minority stakes in growing companies, usually without full control, from Boston, Massachusetts, USA. It states a focus on healthcare & life sciences.
Stated investment criteria
What Ampersand Capital says it buys
Read from Ampersand Capital’s own website in August 2026. This is what the firm says it buys, not what anyone has recorded it buying, and figures are shown in the currency the firm itself used - nothing here is converted. Every line links to the page it was read from.
| Revenue it states | $10m to $100m1 |
| Transaction types | Add-on1 |
| Offices | Boston1 |
| People listed on its team page | 602 |
A stated mandate is a firm’s description of itself and was true of the page on the day it was read; firms widen and narrow what they will look at without updating the site. Ampersand Capital states that it will take either a controlling or a minority stake. The team figure counts the people the firm shows on one team page, so it is a floor rather than a headcount: firms that split their team across tabs or load it in pages will read low. Nothing here is a commitment by Ampersand Capital to consider any particular business, and nothing on this page is represented as being for sale.
Regulatory record
How Ampersand Capital is registered
From this firm's Form ADV, the annual filing every registered and exempt investment adviser makes to the SEC.
| Adviser status | SEC registered |
| Regulatory assets under management | $3.1bn |
| Employees | 38 |
| Private funds advised | 4 · $3.1bn gross |
| SEC adviser number | CRD 161522 |
Portfolio
Disclosed holdings
Companies Ampersand Capital lists on its own website. 1 carry a stated investment year. 1 has a recorded transaction against it in the deal archive.
| Company | Invested | Years held | Recorded transaction |
|---|---|---|---|
| Beacon Intelligence | 2026 | 0 | — |
| ALPCO | — | — | — |
| ANI Pharmaceuticals | — | — | — |
| Adaptas | — | — | — |
| Admera Health | — | — | — |
| Alcami | — | — | — |
| AnaBios | — | — | — |
| Balchem | — | — | — |
| Biologos | — | — | — |
| Bioventus | — | — | — |
| Brammer Bio | — | — | — |
| Clario | — | — | — |
| Confluent | — | — | — |
| Confluent Medical | — | — | — |
| Criver | — | — | — |
| CurTec | — | — | — |
| Curia Global | — | — | — |
| Dynex Technologies | — | — | — |
| Eurofins Viracor | — | — | — |
| Freudenberg Medical | — | — | — |
| GENEWIZ | — | — | $450m 2018 |
| Gannet BioChem | — | — | — |
| Genezen | — | — | — |
| Gyros Protein Technologies | — | — | — |
| ICON Plc | — | — | — |
| Interpace | — | — | — |
| Julius Clinical | — | — | — |
| Leinco | — | — | — |
| Magritek | — | — | — |
| Meadowhawk Biolabs | — | — | — |
| MedPharm | — | — | — |
| NanoImaging Services | — | — | — |
| NeoGenomics | — | — | — |
| Nexcelom | — | — | — |
| Nexelis | — | — | — |
| NovaQuest | — | — | — |
| NuvinkaDx | — | — | — |
| Patheon | — | — | — |
| PerkinElmer | — | — | — |
| Precision Coating | — | — | — |
| ProtaGene | — | — | — |
| Purna | — | — | — |
| Recipharm | — | — | — |
| Resolian | — | — | — |
| Specac | — | — | — |
| StageBio | — | — | — |
| Tjoapack | — | — | — |
| VIVEbiotech | — | — | — |
| Vibalogics | — | — | — |
| alcaminow.com | — | — | — |
| avidbio.com | — | — | — |
| biosynth.com | — | — | — |
| canopybiosciences.com | — | — | — |
| flagshipbio.com | — | — | — |
| ionnl.com | — | — | — |
| iuvobioscience.com | — | — | — |
| kedrion.com | — | — | — |
| lexington-med.com | — | — | — |
| mycovetrus.com | — | — | — |
| p-95.com | — | — | — |
| vantagemedtech.com | — | — | — |
Compiled from Ampersand Capital’s published portfolio page. Where a recorded transaction is shown, that company was the target of a reported deal and has most likely already been realised. Nothing here is represented as being for sale.
Valuation context
Transaction values in Healthcare & Life Sciences
What companies have actually sold for in healthcare & life sciences, across 1,263 recorded transactions.
The full healthcare & life sciences picture - most active acquirers, recent transactions and every investor in the sector.
For owners
Own a healthcare & life sciences business?
The investors on this page acquire companies like yours. A confidential valuation costs nothing, commits you to nothing, and nobody is told you asked.
Request a confidential valuationFor investors
Is this Ampersand Capital?
Claim this profile to correct anything wrong and tell us what you are looking for. We will send matching opportunities as they arise.
Claim or correct this profileTargeted buyer search
Which hundred of these would actually buy your business?
A researched shortlist with a verified deal-team contact for each, and the reason it is on the list. Fixed fee, from $1,450 - or we make the approach for you and hand you the conversations.
Comparable investors
Similar mandates
Other growth equity investors active in healthcare & life sciences.